文献速递肿瘤 PET/CT

多参数PET/MR成像生物标志物与胰腺癌患者总生存期相关

Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-23

这项前瞻性研究纳入63例胰腺癌患者,治疗前接受18F-FDG PET/MRI,评估DCE-MRI、DWI、MRS及葡萄糖代谢参数与总生存期(OS)的关系。中位随访638天,多因素分析显示ADCmin(P=0.011)和TLG/peak比值(P=0.006)是OS的独立预测因素。作者认为TLG/peak比值反映的灌注-代谢不匹配可能比其他PET/MRI成像生物标志物更好地预测OS。

要点

  • 低TNM分期(≦3,P=0.041)、高peak(P=0.006)、高ADCmin(P=0.002)和低TLG(P=0.01)与更好的OS相关。
  • 高TLG/peak比值与较差OS相关(P=0.016)。
  • ADCmin(P=0.011)和TLG/peak比值(P=0.006)是OS的独立预测因素。

核心结论

  • 作者认为TLG/peak比值所反映的灌注-代谢不匹配可能比其他PET/MRI成像生物标志物更好地预测胰腺癌患者OS。

研究设计与样本

  • 前瞻性研究,经机构审查委员会批准,所有参与者均签署知情同意书。
  • 连续纳入63例胰腺癌患者(平均年龄62.7±12岁;男/女,40/23),治疗前接受PET/MRI检查。
  • 评估DCE-MRI参数(peak、IAUC60、Ktrans、kep、ve)、最小表观扩散系数(ADCmin)、胆碱水平、标准化摄取值、代谢肿瘤体积和总病灶糖酵解(TLG)。
  • 采用Kaplan-Meier法和Cox比例风险模型评估影像生物标志物与OS的关系。

主要发现

  • 17例(27%)患者接受了治愈性手术,中位随访时间为638天。
  • 单因素分析显示低TNM分期(≦3,P=0.041)、高peak(P=0.006)、高ADCmin(P=0.002)和低TLG(P=0.01)的患者OS更好。
  • 高TLG/peak比值与较差OS相关(P=0.016)。
  • 多因素分析在校正年龄、性别、肿瘤大小和TNM分期后,ADCmin(P=0.011)和TLG/peak比值(P=0.006)是OS的独立预测因素。
  • 在未接受治愈性手术的患者亚组中,TLG/peak比值是OS的独立预测因素(P=0.013)。

关键数值与推荐

  • 低TNM分期(≦3):P=0.041(单因素分析,与更好OS相关)。
  • 高peak:P=0.006(单因素分析,与更好OS相关)。
  • 高ADCmin:P=0.002(单因素分析,与更好OS相关);多因素分析P=0.011(独立预测因素)。
  • 低TLG:P=0.01(单因素分析,与更好OS相关)。
  • 高TLG/peak比值:P=0.016(单因素分析,与较差OS相关);多因素分析P=0.006(独立预测因素);未接受治愈性手术亚组P=0.013(独立预测因素)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To correlate the overall survival (OS) with the imaging biomarkers of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted imaging (DWI), magnetic resonance spectroscopy, and glucose metabolic activity derived from integrated fluorine 18 fluorodeoxyglucose positron emission tomography (18F-FDG PET)/MRI in patients with pancreatic cancer. METHODS: This prospective study was approved by the institutional review board and informed consent was obtained from all participants. Sixty-three consecutive patients (mean age, 62.7 ± 12 y; men/women, 40/23) with pancreatic cancer underwent PET/MRI before treatment. The imaging biomarkers were comprised of DCE-MRI parameters (peak, IAUC 60 , K trans , k ep , v e ), the minimum apparent diffusion coefficient (ADCmin), choline level, standardized uptake values, metabolic tumor volume, and total lesion glycolysis (TLG) of the tumors. The relationships between these imaging biomarkers with OS were evaluated with the Kaplan-Meier and Cox proportional hazard models. RESULTS: Seventeen (27%) patients received curative surgery, with the median follow-up duration being 638 days. Univariate analysis showed that patients at a low TNM stage (≦3, P = 0.041), high peak (P = 0.006), high ADCmin (P = 0.002) and low TLG (P = 0.01) had better OS. Moreover, high TLG/peak ratio was associated with poor OS (P = 0.016). Multivariate analysis indicated that ADCmin (P = 0.011) and TLG/peak ratio (P = 0.006) were independent predictors of OS after adjustment for age, gender, tumor size, and TNM stage. The TLG/peak ratio was an independent predictor of OS in a subgroup of patients who did not receive curative surgery (P = 0.013). CONCLUSION: The flow-metabolism mismatch reflected by the TLG/peak ratio may better predict OS than other imaging biomarkers from PET/MRI in pancreatic cancer patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chen BB, Tien YW, Chang MC, et al. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29476229. doi:10.1007/s00259-018-3960-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。